Kimaritec is developing new therapies for cancer, by manipulating the body’s protein recycling pathway to drive protein degradation of critical oncoproteins. Cancer remains a disease with high unmet medical need, with many patients succumbing to tumours which become unresponsive to current therapy. Clinicians and patients are looking for new approaches to eradicate or slow progression of cancer. Kimaritec is taking a novel approach to selectively degrade proteins important for cancer growth and metastasis. It is hoped that by harnessing this novel the protein degradation pathway, Kimaritec will develop new anti-cancer therapies.
Company Details
- Founded
- 2020
- Address
- Translational Research Institute, 37 Kent Street,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Brisbane.
- HQ
- Brisbane, Qld
Kimaritec Pty Ltd Questions
Kimaritec Pty Ltd's LinkedIn profile is https://au.linkedin.com/company/kimaritec-pty-ltd
Kimaritec Pty Ltd's industry is
Biotechnology Research
Kimaritec Pty Ltd's top competitors are
De Motu Cordis,
Cardihab,
Microbio,
Vaxxas,
Convergence Medical,
Servatus Ltd,
Exonova Biotech,
Trade And Investment Queensland,
Exintech Pty Ltd,
Cook Medical.
Kimaritec Pty Ltd's categories are Biotechnology Research
Kimaritec Pty Ltd's founding year is 2020
